Background: Rigicon is a newer inflatable penile prostheses (IPP) manufacturer that has produced the Infla10 IPP for countries outside the United States (US) since 2019, with Food and Drug Administration studies for approval of Infla10 in the US presently underway. Aim: This study aims to report the first patient satisfaction, efficacy, and safety from revision data for the newly available Rigicon Infla10 IPP. Methods: A single surgeon’s first 58 patients who underwent Rigicon Infla10 IPP implantation between 2019 and 2023 were included. Most patients (70%) received the Infla10 X (girth expansion) cylinder, and 30% received the Infla10 AX (length and girth expansion) model. Follow-up ranged from 4 to 42 months (median 19 months). Outcomes: Outcomes measured were intraoperative and postoperative complications as well as patient-reported satisfaction. Results: Reoperation was required in 5 patients (8.6%). Complication rates were 1.7% urethral erosion (n = 1), 1.7% infection requiring explant (n = 1), and 5% mechanical malfunction due to tubing breakage at pump junction (n = 3). The tubing issue was addressed by the manufacturer, resulting in no additional mechanical concerns. Kaplan–Meier analysis demonstrated rates of cumulative survival of the device at 12, 24, and 36 months were 96.6%, 93.8%, and 78.2%, respectively. Overall, 53 patients (91.4%) were satisfied at 6 months postoperatively and would recommend the procedure. Diminished satisfaction was due to perceived penile shortening in 3 patients (5.1%) and difficulty learning pump cycling in 2 patients (3.4%). Clinical implications: This single surgeon series demonstrates high rates of patient satisfaction with appropriate early safety from revision. Strengths and limitations: Limitations include the retrospective nature of this study and short-term follow-up. Additional prospective studies incorporating a larger number of patients are warranted. Conclusion: While very new in the marketplace, the Infla10 IPP shows promising early satisfaction, efficacy, and safety from revision.
Introduction: Inflatable penile prosthesis implantation is a well-established treatment option for men with erectile dysfunction refractory to conservative therapies. However, patient-reported outcome data for the Rigicon Infla10 prosthesis remain limited. This study aimed to evaluate 12-month patient-reported outcomes following primary implantation of Rigicon Infla10 X and Infla10 AX devices and to explore potential differences according to implant model and pump type. Methods: This retrospective single-center, single-surgeon cohort study included 275 patients who underwent primary Rigicon Infla10 X or Infla10 AX implantation between 2021 and 2024 and completed 12-month follow-up. Erectile function was assessed using the International Index of Erectile Function–Erectile Function domain (IIEF-EF), while postoperative satisfaction was evaluated using the Quality of Life and Sexuality with Penile Prosthesis (QoLSPP) questionnaire. Ease of inflation and deflation was assessed using a 10-point numeric rating scale. Subgroup analyses were performed according to implant model and pump type. Results: Mean preoperative IIEF-EF score increased from 6.09 ± 1.47 to 24.07 ± 1.78 at 12 months. The overall mean QoLSPP total score was 4.19 ± 0.16. QoLSPP scores did not differ significantly between the Infla10 X and Infla10 AX groups (4.20 ± 0.18 vs. 4.18 ± 0.16; P = .436). Patients using the Pulse pump reported significantly higher ease-of-inflation and ease-of-deflation scores compared with those using the earlier-generation pump (both P < .001), whereas QoLSPP total scores were similar between pump groups (P = .821). The overall complication rate was 5.5%, and device infection occurred in one patient (0.4%). Discussion: Primary Rigicon Infla10 implantation was associated with substantial improvement in erectile function and favorable patient-reported outcomes at 12 months. Although the Pulse pump was associated with improved ease-of-use ratings, these differences did not translate into higher overall satisfaction scores. Interpretation of pump-related comparisons should be cautious because pump type was era-dependent and not randomly assigned. Prospective studies with longer follow-up are warranted to confirm these findings and further evaluate device-related outcomes.
13 August 2026 in International Journal Of Impotence Research